112 related articles for article (PubMed ID: 3391423)
1. Concordance of combination and single agent chemosensitivity prediction in ovarian carcinoma using the subrenal capsule xenograft assay (SRCA).
Stratton JA; Rettenmaier MA; Kucera PR; Berman ML; DiSaia PJ
Gynecol Oncol; 1988 Jul; 30(3):416-21. PubMed ID: 3391423
[TBL] [Abstract][Full Text] [Related]
2. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
[TBL] [Abstract][Full Text] [Related]
3. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
Stratton JA; Kucera PR; Rettenmaier MA; Dobashi K; Micha JP; Braly PS; Berman ML; DiSaia PJ
Gynecol Oncol; 1986 Nov; 25(3):302-10. PubMed ID: 3781341
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced and recurrent endometrial carcinoma: correlation of patient response to hormonal and cytotoxic chemotherapy and the response predicted by the subrenal capsule chemosensitivity assay.
Stratton JA; Mannel RS; Rettenmaier MA; Berman ML; DiSaia PJ
Gynecol Oncol; 1989 Jan; 32(1):55-9. PubMed ID: 2535831
[TBL] [Abstract][Full Text] [Related]
5. Mitotic index in the subrenal capsule assay as an indicator of the chemosensitivity of ovarian cancer.
Suonio E; Lipponen P; Mäenpää J; Syrjänen K; Kangas L; Tuomisto L
Cancer Chemother Pharmacol; 1997; 41(1):15-21. PubMed ID: 9443609
[TBL] [Abstract][Full Text] [Related]
6. Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.
Venesmaa P; Ylikorkala O
Br J Cancer; 1991 Jan; 63(1):84-6. PubMed ID: 1899195
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitizing effect of an antiestrogen, toremifene, on ovarian cancer.
Mäenpää J; Sipilä P; Kangas L; Karnani P; Grönroos M
Gynecol Oncol; 1992 Sep; 46(3):292-7. PubMed ID: 1388131
[TBL] [Abstract][Full Text] [Related]
8. Subrenal capsule assay as a test to predict the effectiveness of chemotherapy in choriocarcinoma.
Ogino M; Sakamoto T; Yamamoto T; Mori H; Okinaga S; Arai K
Gynecol Oncol; 1990 Jul; 38(1):32-6. PubMed ID: 2354824
[TBL] [Abstract][Full Text] [Related]
9. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
10. Chemosensitivity testing of nonsolid tumors by the subrenal-capsule implant assay.
Stratton JA; Micha JP; Rettenmaier MA; Braley PS; DiSaia PJ
Gynecol Oncol; 1984 Feb; 17(2):185-8. PubMed ID: 6584388
[TBL] [Abstract][Full Text] [Related]
11. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
12. Combined cyclophosphamide, adriamycin and cis-platinum in advanced ovarian cancer resistant to chlorambucil and cis-platinum.
Mann GJ; Malden LT; Solomon HJ; Tattersall MH
Gynecol Oncol; 1985 Jun; 21(2):215-9. PubMed ID: 3886497
[TBL] [Abstract][Full Text] [Related]
13. The subrenal capsule assay and gynecological cancer: five years of experience.
Mäenpää J; Kangas L; Söderström KO; Grönroos M
Ann Chir Gynaecol Suppl; 1987; 202():83-7. PubMed ID: 2444148
[TBL] [Abstract][Full Text] [Related]
14. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
15. [Clinical application of subrenal capsule assay in ovarian cancer].
Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
[TBL] [Abstract][Full Text] [Related]
16. Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Barlow JJ; Lele SB; Malfetano JH; McPhee ME
J Surg Oncol; 1983 Dec; 24(4):329-31. PubMed ID: 6418977
[TBL] [Abstract][Full Text] [Related]
17. [Responsiveness of gynecological malignancies to oral antitumor agents in subrenal capsule assay and individualization of oral adjuvant chemotherapy].
Sekiguchi I; Suzuki M; Aida I; Tamada T; Nishida M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 May; 42(5):437-42. PubMed ID: 2115558
[TBL] [Abstract][Full Text] [Related]
18. [An experimental study on subrenal capsule assay (SRCA)--problems for the use of immunosuppressive agents].
Kikuchi H; Asamura M; Gamoh M; Okuno M; Wakui A; Takahashi T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2607-12. PubMed ID: 2774591
[TBL] [Abstract][Full Text] [Related]
19. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
[TBL] [Abstract][Full Text] [Related]
20. Predictive testing of vulvar and cervical cancers to chemotherapy by the subrenal capsule assay.
Mäenpää J; Kangas L; Grönroos M
Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1141-6. PubMed ID: 4076281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
